Theriva Biologics, INC DEF 14A proxy statements

Theriva Biologics, Inc. has announced its 2026 Annual Meeting of Stockholders to be held on August 3, 2026, to vote on key proposals including director elections, auditor ratification, stock incentive plan amendments, and share authorization.

Theriva Biologics has scheduled a special meeting for June 5, 2026, to seek stockholder approval for the issuance of shares related to a 2025 private placement warrant exercise.

Theriva Biologics, Inc. is calling a Special Meeting of Stockholders on April 9, 2026, to approve the issuance of up to 16,184,560 common shares from warrant exercises and an adjournment proposal.

Theriva Biologics, Inc. is calling a Special Meeting of Stockholders on February 11, 2026, to approve the issuance of up to 16,184,560 common shares from warrant exercises and an adjournment proposal.

Theriva Biologics, Inc. is seeking shareholder approval to issue up to 16.18 million common shares upon the exercise of warrants from a recent private placement.

Theriva Biologics, Inc. is holding a Special Meeting to approve the issuance of up to 16.18 million common shares from new warrant exercises, a condition for potential capital.

Theriva Biologics, Inc. has issued its proxy statement for the 2025 Annual Meeting, proposing the election of four directors, ratification of its independent auditor, and a significant increase in its stock incentive plan shares to attract and retain talent, against a backdrop of substantial net losses and declining shareholder returns.

Theriva Biologics is holding its 2024 Annual Meeting of Stockholders on October 31, 2024, to vote on several proposals, including the election of directors, ratification of the accounting firm, and amendments to the stock incentive plan and articles of incorporation.